Fig 1: (A) CD62L/CD45RA expression in the CD8 population with (red) or without (blue) transfection of the anti-CD3 CAR mRNA. N=5; 5 independent T-cell donors. p-value: 0.2251 for CD45RA+ CD62L+, 0.7472 for CD45RA+ CD62L–, 0.2185 for CD45RA-CD62L–, and 0.2327 for CD45RA-CD62L+ : (B) PD1 and LAG3 expression in the whole T-cell population with (red) or without (blue) transfection of the anti-CD3 CAR mRNA. N=5, 5 independent T-cell donors p-value: 0.1307 for PD1, 0.5295 for LAG3, 0.3597 for PD1/LAG3 and 0.7521 for double negatives. (C) Antigen-dependent proliferation of CAR T-cells with (red) or without (blue) transfection of the anti-CD3 CAR mRNA over a 10-day period. N=7; five independent T-cell donors. (D) Target cell killing over a period of 3 days. UCAR T-cells engineered with (red) or without (blue) transfection of the anti-CD3 CAR mRNA. N=3; three independent T-cell donors. Significance is determined by a standard unpaired t-test, *p = 0.05, **p = 0.01.